Related Experiment Video
Updated: Feb 4, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
[Noble Heart Failure Therapy Using Food Compositions]
Tatsuya Morimoto1,2,3, Masafumi Funamoto1,2, Yoichi Sunagawa1,2,3
1Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka.
Insights
Curcumin, a natural compound, shows promise in preventing heart failure. Highly absorbable formulations like Theracurmin may improve heart function and patient survival rates.
Area of Science:
- Cardiovascular Research
- Natural Product Chemistry
- Pharmacology
Background:
- Hemodynamic stresses (hypertension, myocardial infarction) activate neurohumoral factors, progressing heart failure.
- Current treatments (ARBs, ACE inhibitors, β-blockers) target extracellular molecules but have limited long-term efficacy.
- Novel pharmacological approaches are needed to improve heart failure survival rates.
Purpose of the Study:
- To review the potential clinical applications of curcumin, a natural polyphenol, for heart failure.
- To focus on Theracurmin, a novel, highly absorbable curcumin formulation, for cardiovascular diseases.
- To discuss preliminary data suggesting Theracurmin's benefits for left ventricular diastolic function.
Main Methods:
- Review of previous studies on curcumin's cardioprotective effects in animal models.
- Discussion of advancements in curcumin formulation (nanoparticle, micellization) to enhance bioavailability.
- Summary of ongoing and completed clinical trials investigating Theracurmin for heart failure-related conditions.
Main Results:
- Curcumin demonstrated efficacy in preventing heart failure in rat models.
- Highly absorbable curcumin formulations, like Theracurmin, overcome bioavailability challenges.
- Preliminary data suggest Theracurmin may enhance left ventricular diastolic function.
Conclusions:
- Curcumin, particularly highly absorbable formulations like Theracurmin, holds significant potential for treating heart failure.
- Further clinical trials are warranted to establish Theracurmin's efficacy and safety in heart failure patients.
- Targeting intracellular pathways with novel curcumin formulations could offer a new therapeutic strategy.
Abstract:
Hemodynamic stresses, including hypertension and myocardial infarction, activate neurohumoral factors such as the sympathetic nervous system and the renin-angiotensin system, and can lead to the progression of heart failure. Established pharmacological agents such as angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, and β-blockers target extra-cellular molecules and receptors on the cell membrane. These agents have shown some efficacy for the treatment of heart failure, but the long-term survival rate of patients with heart failure remains low. Additional effective pharmacological approaches are urgently required. Our previous studies have demonstrated that curcumin, a natural polyphenol derived from the root of Curcuma longa, prevented the development of heart failure in rat models of myocardial infarction and hypertensive heart disease. However, until recently curcumin's poor water solubility and extremely low bioavailability have presented serious challenges to its clinical applicability. In recent years, highly absorbable curcumin preparations have been developed using methods such as nanoparticle formation and micellization, and there are now high expectations for their wide clinical application. Our group has developed a highly absorbable curcumin formulation called Theracurmin using nanoparticulation and surface processing techniques. Our preliminary data indicated that Theracurmin may improve left ventricular diastolic function. Furthermore, we have already completed and are currently carrying out several clinical trials using Theracurmin against heart failure-related diseases. This paper summarizes and discusses the potential clinical applications of curcumin, focusing on our highly absorbable curcumin formulation, Theracurmin.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Noble Gases
The elements in group 18 are noble gases (helium, neon, argon, krypton, xenon, and radon). They earned the name “noble” because they were assumed to be nonreactive since they have filled valence shells. In 1962, Dr. Neil Bartlett at the University of British Columbia proved this assumption to be false.
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure Drugs: Diuretics

